Curcumin in Treating Patients With Familial Adenomatous Polyposis

• Status: Completed
• Trial end date: 2016-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This randomized phase II trial studies curcumin in treating patients with familial adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal polyps or colorectal neoplasia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Curcumin

Criteria

Inclusion Criteria:

• Patients with familial adenomatous polyposis who have undergone subtotal colectomy with ileorectal anastomosis, total colectomy with ileo-anal pull through (reservoir), and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or reservoir

• Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis without current lower tract adenomatous polyposis i.e. status/post (s/p) ileostomy

Exclusion Criteria:

• Female patients of childbearing age not on effective birth control

• Pregnant women

• White blood cell count (WBC) < 3500/ml

• Platelet count < 100,000/ml

• Blood urea nitrogen (BUN) > 25mg%

• Creatinine > 1.5mg%

• Patients unable to stop non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, curcumin, tumeric, calcium, vitamin D, green tea, or polyphenol E supplements for the duration of the trial

• Malignancy other than nonmelanoma skin cancer

• Active bacterial infection

• Patients with symptoms of active gastroesophageal reflux disease (GERD) (symptomatic despite medication or current erosive esophagitis on endoscopy)

• Patients with a history of peptic ulcer disease

• Patients on warfarin or plavix